Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06436040 | Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma | unknown | — | 40 | Tang-Du HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT05878028 | L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC | unknown | Phase 2 | 33 | Quanli GaoOTHER_GOV | 1 | May 23, 2024 | clinicaltrials |
| NCT03724500 |
| Clinical Significance of Circulating Tumor Cell in Non Small Cell Lung Cancer |
| unknown |
| — |
| 65 |
| Chang Gung Memorial HospitalOTHER |
| 1 |
| May 22, 2024 |
| clinicaltrials |
| NCT06424821 | Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC(LungCadX) | unknown | Phase 2 | 54 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT06422546 | A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC(pre-FLAME) | unknown | — | 950 | Beijing Cancer Prevention & Treatment SocietyOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT04909073 | Observational Study of Afatinib 30 mg Daily | unknown | — | 69 | National University Hospital, SingaporeOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT06410040 | A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis | unknown | — | 28 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06406608 | Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer | unknown | N/A | 20 | Henan Cancer HospitalOTHER_GOV | 1 | May 9, 2024 | clinicaltrials |
| NCT05354102 | A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 | unknown | Phase 1 | 11 | Biomica Ltd.INDUSTRY | 1 | May 7, 2024 | clinicaltrials |
| NCT06115239 | QOL After SURGERY and ADJUVANT Treatment | unknown | — | 200 | University of SalamancaOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT03833440 | Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance(PIONeeR) | unknown | Phase 2 | 114 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT04193956 | POINTING: Clinical Cohort Study of Patients With Melanoma and NSCLC Receiving Checkpoint Inhibitors(POINTING) | unknown | — | 3,500 | University Medical Center GroningenOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT06394427 | Neoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung Cancer | unknown | — | 250 | West China HospitalOTHER | 0 | May 1, 2024 | clinicaltrials |
| NCT04622007 | Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)(KICKSTART) | unknown | Phase 2 | 68 | Effector TherapeuticsINDUSTRY | 3 | Apr 30, 2024 | clinicaltrials |
| NCT04085250 | Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy | unknown | Phase 2 | 264 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06374160 | Exercise in Patients With Advanced Non-small Cell Lung Cancer(BREATH) | unknown | N/A | 104 | University Hospital, EssenOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT05260606 | Imaging Biomarkers for Immune Checkpoint Inhibitor Treatment in Patients With Non-small Cell Lung Cancer(IBFIC) | unknown | — | 100 | Samsung Medical CenterOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05240131 | A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). | unknown | Phase 1 / Phase 2 | 88 | Galecto Biotech ABINDUSTRY | 3 | Apr 12, 2024 | clinicaltrials |
| NCT04909684 | Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC(DEDICATION-1) | unknown | Phase 3 | 750 | Radboud University Medical CenterOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05519293 | Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation | unknown | Phase 1 / Phase 2 | 76 | RedCloud BioINDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05552781 | H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC | unknown | Phase 1 / Phase 2 | 76 | RedCloud BioINDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06357598 | Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer(PILOT) | unknown | Phase 4 | 30 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06349252 | Survival Validation and Gene Mutations of N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer | unknown | — | 1,263 | Fudan UniversityOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT02991924 | Risk Factors of Medistinal Metastasis in Endoscopic Staging of Lung Cancer | unknown | — | 600 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 4, 2024 | clinicaltrials |
| NCT05254119 | DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTS(REGISTURK-LUNG) | unknown | — | 6,000 | Mahmut GumusNETWORK | 1 | Apr 4, 2024 | clinicaltrials |
| NCT04772235 | Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients(TOTEM) | unknown | Phase 1 | 32 | Instituto Oncológico Dr RosellOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06341387 | Volatolomic and Proteomic Profile for Early Diagnosis of Lung Cancer | unknown | — | 200 | European Institute of OncologyOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341530 | Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 33 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341660 | To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 30 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06339242 | A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis | unknown | Phase 2 | 30 | Jiangsu Province Nanjing Brain HospitalOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06334757 | Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure | unknown | Phase 2 | 46 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06332287 | A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis | unknown | Phase 2 | 25 | Jiangsu Province Nanjing Brain HospitalOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06331650 | A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer | unknown | Phase 2 | 30 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT02619448 | Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC | unknown | Early Phase 1 | 12 | State University of New York - Upstate Medical UniversityOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06328049 | A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC | unknown | Phase 2 | 30 | Taixing People's HospitalOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT04903873 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 110 | EutilexINDUSTRY | 2 | Mar 15, 2024 | clinicaltrials |
| NCT06285058 | Deep Learning Model Predicts Pathological Complete Response of Lung Cancer Following Neoadjuvant Immunochemotherapy | unknown | — | 1,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Mar 13, 2024 | clinicaltrials |
| NCT05004974 | Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 20 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05872867 | Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) | unknown | Phase 1 | 54 | Wellmarker BioINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06277674 | Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI | unknown | Phase 2 | 20 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT04780217 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06287320 | The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer | unknown | — | 200 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT03865511 | MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib(MELROSE) | unknown | Phase 2 | 150 | Nantes University HospitalOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06281860 | Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration(PITHAC) | unknown | Phase 1 | 39 | Dr Jean Yannis PERENTESOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT03274479 | PBF-1129 in Patients With NSCLC | unknown | Phase 1 | 18 | Palobiofarma SLINDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05163249 | Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC(FLOWERS) | unknown | Phase 2 | 44 | Guangdong Association of Clinical TrialsOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05602259 | PROspective Trial on EOsinophilia in Non-Small Cell Lung Cancer (NSCLC).(PROTEON) | unknown | N/A | 200 | Centre Hospitalier Universitaire de LiegeOTHER | 1 | Feb 9, 2024 | clinicaltrials |
Data updated 23 days agoSource updated May 30, 2024source: clinicaltrials